IL-37 protects against obesity-induced inflammation and insulin resistance

Dov B. Ballak1, Janna A. van Diepen1, Alexander R. Moschen2, Henry J. Jansen1, Anneke Hijmans1, Gert-Jan Groenhof1, Floris Leenders1, Philip Bufler2, Mark V. Boekschoten3, Michael Müller3, Sander Kersten3, Suzhao Li4, SooHyun Kim5, Hadar Eini6, Eli C. Lewis6, Leo A.B. Joosten1, Herbert Tilg7, Mihai G. Netea1, Cees J. Tack1, Charles A. Dinarello1,4 & Rinke Stienstra1,3

Cytokines of the IL-1 family are important modulators of obesity-induced inflammation and the development of systemic insulin resistance. Here we show that IL-1 family member IL-37, recently characterized as an anti-inflammatory cytokine, ameliorates obesity-induced inflammation and insulin resistance. Mice transgenic for human IL-37 (IL-37tg) exhibit reduced numbers of adipose tissue macrophages, increased circulating levels of adiponectin and preserved glucose tolerance and insulin sensitivity after 16 weeks of HFD. In vitro treatment of adipocytes with recombinant IL-37 reduces adipogenesis and activates AMPK signalling. In humans, elevated steady-state IL-37 adipose tissue mRNA levels are positively correlated with insulin sensitivity and a lower inflammatory status of the adipose tissue. These findings reveal IL-37 as an important anti-inflammatory modulator during obesity-induced inflammation and insulin resistance in both mice and humans, and suggest that IL-37 is a potential target for the treatment of obesity-induced insulin resistance and type 2 diabetes.
Obesity has reached epidemic proportions worldwide and predisposes to the development of metabolic diseases, including type 2 diabetes and cardiovascular diseases. In obesity, adipocytes produce pro-inflammatory cytokines and chemokines that can attract and activate macrophages and other immune cells, resulting in chronic low-grade inflammation. The enhanced inflammatory status, illustrated by the production of pro-inflammatory cytokines, directly interfere with the insulin signalling pathway, eventually leading to systemic insulin resistance and the subsequent development of type 2 diabetes.

Multiple pro-inflammatory cytokines have been identified that play a detrimental role in obesity-induced inflammation and insulin resistance, such as interleukin (IL)-1β and tumour necrosis factor-α (TNFα). However, cytokines that are able to restore the immunological misbalance in obesity have been less well studied. The IL-1 family consists of 11 members, of which IL-1α, IL-1β, IL-1 receptor antagonist and IL-18 have been shown to play a pivotal role during obesity by modulating inflammatory responses. Only recently has IL-1 family member IL-37, isolated in situ in the year 2000, been identified for its anti-inflammatory actions by inhibiting innate responses.

During acute and chronic inflammation, IL-37 shifts the cytokine balance away from excessive inflammation, thereby showing potency as a key factor to restore the inflammatory balance in obesity. The IL-37 gene has been mapped to chromosome 2 and exists in five splice variants. IL-37b is the most complete variant containing five of the six exons and lacking a signal peptide. The IL-37 precursor contains a classic caspase-1 cleavage site, and caspase-1 processing appears to be required for nuclear translocation of IL-37 and its intracellular anti-inflammatory properties. An instability element in exon 5 is known to control IL-37 messenger RNA expression. Subsequently, in the absence of inflammation, mRNA levels of IL-37 are rapidly degraded. In contrast, an inflammatory stimulus stabilizes IL-37 mRNA levels, thereby permitting its anti-inflammatory actions.

Previous studies have shown that IL-37 transgenic mice are protected from colitis and lipopolysaccharide (LPS)-induced shock.

In the present study, we investigated whether IL-37 can counteract obesity-induced adipose tissue inflammation and protect against the development of insulin resistance. This was tested by examining adipose tissue samples from 80 humans for the expression of IL-37 and its relationship to inflammatory and metabolic markers. We also studied the effects of high-fat diet (HFD) in a unique human IL-37 transgenic mouse model and the in vitro properties of IL-37 on adipocyte function, insulin and AMPK signalling. We provide evidence for a role of IL-37 in ameliorating inflammation and insulin sensitivity in obesity.

**Results**

**IL-37 is expressed in human adipose tissue.** First, we evaluated the gene expression of IL-1 family members, including IL-37, in human adipose tissue in mature adipocytes (MAs) and stromal vascular cells (SVF) isolated from seven subjects. Whereas IL-1β, IL-1Ra and IL-18 showed higher expression in SVF, IL-37 was the only cytokine with higher mRNA levels in MA compared with SVF (Fig. 1a). mRNA analysis of paired adipose tissue samples of individuals demonstrated clear expression of IL-37 in adipose tissue, which was similar in visceral adipose compared with subcutaneous adipose tissue (Fig. 1b). In addition, western blot analysis revealed the presence of IL-37 in human adipose tissue at ~37 kDa (Fig. 1c). However, in adipose tissue IL-37 migrates at ~37 kDa, likely to be due to homodimerization, which was also reported elsewhere.

Moreover, the presence of IL-37 in human adipose tissue was confirmed by measuring the protein by a specific enzyme-linked immunosorbent assay (Supplementary Fig. 1).

**IL-37 reduces diet-induced obesity in mice.** To date, no complete mouse homologue for IL-37 has been found. Therefore, to examine the properties of IL-37 in a model of obesity in vivo, we employed a transgenic mouse strain expressing human IL-37 (IL-37tg) in all cells using a cytomegalovirus promoter. The animals were fed High fat diet (HFD) (45% kcal derived from fat) or a control low-fat diet (LFD) (10% kcal derived from fat) for 16 weeks, and body weight gain and food intake were compared with wild-type (WT) animals (Fig. 2a). Starting body weight was similar between the WT and IL-37tg animals, yet body weight gain was significantly lower in HFD-fed IL-37tg mice compared with WT animals (~41% on HFD and ~46% on LFD) (Fig. 2b), even though total caloric intake was similar in both genotypes (Fig. 2c). In line with lower body weight and epididymal white adipose tissue (WAT) mass (Fig. 2d), adipocyte size was smaller in the IL-37tg mice compared with WT animals (Fig. 2e), and...
paralleled by lower leptin (Fig. 2f) and strikingly higher plasma adiponectin levels (Fig. 2g).

IL-37 lowers liver and plasma lipids. After HFD feeding, liver weight was lower in the presence of human IL-37 (Fig. 2h), which was paralleled by lower liver hepatic triglyceride content in HFD-fed IL-37tg mice as compared with WT animals (Fig. 2j) and by reduced levels of hepatic steatosis on HFD feeding, as visualized by haematoxylin and eosin staining (Fig. 2i). However, no significant differences were found in MCP-1 and F4/80 gene expression levels in the liver (Fig. 2k,l). Plasma cholesterol was significantly lower after HFD feeding in IL-37 animals compared with HFD-fed WT (Fig. 2m). Free fatty acid (FA) and triglyceride

Figure 2 | IL-37 reduces diet-induced obesity in mice. IL-37tg and WT mice were fed an LFD or HFD for 16 weeks. (a) Body weight development and (b) body weight gain on LFD or HFD feeding. (c) Total caloric intake during 16 weeks of LFD or HFD. (d) Epididymal WAT (eWAT) weight after 16 weeks of LFD or HFD and (e) adipocyte size. Plasma concentrations of (f) leptin and (g) adiponectin after diet intervention. (h) Liver weights, (i) haematoxylin and eosin (H&E) staining of liver sections; magnification ×20 and (j) hepatic triglyceride (TG) content. qPCR analysis of macrophage infiltration markers F4/80 (k) and MCP-1 (l) in liver. (m) Plasma cholesterol, (n) free FAs and (o) triglycerides after 16 weeks of LFD or HFD. (p) H&E staining of brown adipose tissue; magnification ×20. n = 10 mice per group. Error bars are shown as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001 (t-test or one-way analysis of variance). TG, triglycerides; FFA, free fatty acids.
plasma levels in the animals showed similar tendencies towards lower values in **IL-37tg** animals compared with WT mice after the HFD intervention (Fig. 2n,o).

To learn more about potential mechanisms that may explain lower body weight and amelioration in plasma lipid profile, we examined the brown adipose tissue, known to oxidize FAs for heat production. Owing to the large energy consumption, brown adipose tissue (BAT) highly contributes to plasma triglyceride clearance. Although UCP-1 and PGC-1α were not altered in the **IL-37tg** mice compared with WT (Supplementary Fig. 2a,b), we observed a marked reduction in BAT lipid accumulation, in **IL-37tg** mice fed HFD compared with WT animals (Fig. 2p).

**IL-37 ameliorates diet-induced insulin resistance.** After HFD feeding, lower plasma insulin levels were observed in **IL-37tg** mice compared with WT mice, suggestive of preserved insulin sensitivity (Fig. 3a). Therefore, we performed an insulin tolerance test (ITT) and oral glucose tolerance test (oGTT). The ITT revealed that **IL-37tg** animals were partially protected against obesity-induced insulin resistance (Fig. 3b). In addition, the oGTT test demonstrated that **IL-37tg** animals had improved glucose tolerance on HFD feeding as compared with WT mice (Fig. 3c).

**Acute effects of IL-37 on glucose tolerance.** To determine whether the beneficial effects of IL-37 on insulin sensitivity were independent of differences in body weight, we fed WT and **IL-37tg** animals a short-term HFD containing 60% kcal derived from fat for 4 days. The 4-day diet intervention did not affect body weight (Supplementary Fig. S3). An oral GTT test revealed that the HFD-fed WT animals developed glucose intolerance as compared with the LFD-fed mice. In contrast, in the HFD-fed **IL-37tg** animals, glucose tolerance was preserved as compared with the mice receiving the LFD (Fig. 3d), suggesting that IL-37 directly ameliorates the adverse effects on glucose tolerance induced by chronic HFD feeding, and that this effect is independent of changes in body weight.

We further assessed whether the improved glucose tolerance in the **IL-37tg** mice was due to differences in the insulin-producing β-cells. Islets were therefore stained for insulin and then mean staining intensity was measured as marker for insulin content. In **IL-37tg** mice, mean insulin staining intensity was lower compared with WT mice in both LFD- and HFD-fed mice (Supplementary Fig. 4a). In addition, islet hypertrophy was also observed in WT mice (P = 0.06 (one-way analysis of variance)). However, in **IL-37tg** mice, islet hypertrophy was not present (Supplementary Fig. 4b,c). Moreover, no differences were seen in the number of macrophages in the islets (Supplementary Fig. 4d). Together, these observations suggest preserved β-cell function and thereby improved metabolic control in **IL-37tg** mice after HFD.

**IL-37 directly improves insulin sensitivity.** We subsequently investigated the effect of IL-37 on insulin sensitivity using an in vitro approach. We revealed that silencing IL-37 hampers insulin signalling in human HepG2 cells that were stimulated with TNF-α or tunicamycin as inducers of insulin resistance. Stimulation of these cells with either TNF-α or tunicamycin resulted in a significant increase of steady-state levels of IL-37 mRNA after 4 and 8 h (Fig. 3e). As shown in Fig. 3f, small interference RNA (siRNA)-mediated targeting to silence endogenous IL-37 (see Supplementary Fig. S5) significantly reduced activation of insulin receptor substrate 1 (IRS-1) as measured by tyrosine (Tyr) 941 phosphorylation. As a consequence, phosphorylation of the downstream effector molecule AKT was also reduced as compared with scrambled siRNA-treated cells. As shown in Fig. 3g, these differences could be partly explained by the increased activation of the inflammatory kinases ERK1/2, JNK and IKK α/β in cells silenced for IL-37. These kinases are known to cause insulin resistance via inhibition of the insulin signalling pathway, for example, by inhibition of IRS-1 (ref. 34). IL-37 downregulates the phosphorylation of these kinases as reported before.

**IL-37 ameliorates diet-induced adipose tissue inflammation.** Furthermore, we investigated whether the **IL-37tg** mice were protected against HFD-induced adipose tissue inflammation, which may explain the improvement in insulin sensitivity. Therefore, we first investigated the adipose tissue of **IL-37tg** and WT mice for the presence of different immune cells using fluorescence-activated cell sorting (FACS) analysis of the stromal vascular fraction after 16 weeks of HFD feeding. Macrophage numbers were lower in **IL-37tg** mice (F4/80 + CD11b −, −20%, P < 0.05 (t-test); Fig. 4a). Similar reductions of other pro-inflammatory cells were observed for NK cells (NK1.1 +, −46%, P < 0.05 (t-test); Fig. 4b) and cytotoxic T cells (CD3 + CD8 +, −32%, P < 0.05 (t-test); Fig. 4c), whereas there was no change in the amount of regulatory T cells (CD3 + CD4 +, nonsignificant (t-test); Fig. 4d) in the **IL-37tg** animals compared with WT animals fed the HFD. The reduction in pro-inflammatory status of the adipose tissue in the presence of **IL-37** was confirmed by quantitative PCR (qPCR) analysis for various macrophage markers. F4/80, CD11c and MCP-1 gene expression levels were all substantially lower in HFD-fed **IL-37tg** mice when compared with WT mice (Fig. 4e-g). In line with these data, immunohistochemistry demonstrated a reduced number of F4/80 + cells in the adipose tissue of **IL-37tg** mice (Fig. 4i) and a reduced amount of crown-like structures as compared with WT mice fed the HFD (Fig. 4h). Next, we further explored whether recIL-37 limits adipose tissue inflammation in Ob/Ob mice, an established obese mouse model with enhanced adipose tissue inflammation. Therefore, Ob/Ob mice were treated intraperitoneally with recIL-37 for 2 weeks. IL-1β levels were robustly reduced (−93%, P < 0.01 (t-test)), as was the secretion of pro-inflammatory IL-6 and CXCL1 in WAT of animals treated with recIL-37, as compared with animals receiving vehicle only (Fig. 4j-l). Moreover, similar changes were seen in mRNA expression of these cytokines, although the treatment did not change the number of macrophages that were present in the adipose tissue (Supplementary Fig. 7).

To further understand the molecular pathways affected by IL-37 during development of obesity, a microarray analysis of the whole adipose tissue from HFD-fed WT and **IL-37tg** animals was performed. Hierarchical clustering of the microarray results led to a distinct separation of WT versus **IL-37tg** animals fed the HFD for 16 weeks (Supplementary Fig. S8). Compared with the WT mice, 1,125 genes were significantly upregulated and 793 genes were downregulated in the adipose tissue of the **IL-37tg** animals (P < 0.01).

Figure 5a shows the pathways that were regulated significantly different in the **IL-37tg** mice compared with WT mice, when analysed using Cytoscape. In the adipose tissue of the **IL-37tg** animals, several immune and inflammatory pathways including Toll-like receptor (TLR) signalling were downregulated compared with the WT mice. In line with downregulation of TLR signalling pathways, qPCR analysis of TLR-2 and TLR-4, known to mediate obesity-induced adipose tissue inflammation, revealed reduced expression levels of both TLRs in adipose tissue of HFD-fed **IL-37tg** animals as compared with WT mice (Supplementary Fig. S9b,c). Noticeably, expression levels of TLR-1 increased similarly in both genotypes (Supplementary Fig. S9a).
In addition, the microarray data revealed upregulation of a cluster of genes related to mitochondrial and oxidative phosphorylation in adipose tissue of HFD-fed IL-37tg animals as compared with WT mice, suggesting that IL-37 may directly influence specific metabolic pathways.

**IL-37 affects AMPK activation in macrophages and adipocytes.** Although AMPK is a central regulator of cellular metabolism, its activation also results in several anti-inflammatory effects, for example, by reduced production of pro-inflammatory cytokines in response to LPS. Activation of AMPK is known to have...
Ob/ob mice were injected intraperitoneally with 1 ug recIL-37 for 1 h and displayed reduced adipocyte differentiation as indicated by reduced mRNA expression of FABP4 and PPARγ. Indeed, the number of CD68+ cells was significantly lower in recIL-37-treated mice. n = 4 mice per group for microanalysis, for cytometry N = 5, otherwise n = 10 mice per group. Error bars are shown as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001 (t-test or one-way analysis of variance). CLS, crown-like structures.

Deep effects on adipose tissue, including anti-obesity effects41. In related studies, transfection of THP-1 cells with IL-37 resulted in >40% increase in phosphorylation of AMPK associated with a >60% reduction in mammalian target of rapamycin21. Therefore, we subsequently evaluated whether IL-37 affects AMPK signalling in adipocytes. Murine adipocytes were treated with recombinant IL-37 precursor IL-37 for 1 h and phosphorylation of AMPK was subsequently measured. Adipocytes that were stimulated with recIL-37 displayed increased phosphorylation of AMPK (Fig. 5b), revealing that IL-37 activates AMPK signalling. In addition, the activity of ACC, an important downstream target of AMPK, was also increased by recIL-37 treatment (Fig. 5b). Furthermore, Sestrin 2, an important activator of AMPK, was increased in the presence of IL-37 in the HFD mice, suggesting a possible explanation by which AMPK activity was increased (Supplementary Fig. 10). As activation of AMPK is known to potently inhibit adipocyte differentiation18, adipocytes from WT mice were subsequently differentiated in the presence of recIL-37, and mRNA levels of lipogenic genes PPARγ and FABP4 were measured. Indeed, recIL-37-treated cells displayed reduced adipocyte differentiation as indicated by reduced mRNA expression of FABP4 and PPARγ (Fig. 5c,e).

In bone marrow-derived macrophages (BMDMs) from IL-37tg animals, pAMPK levels were elevated compared with WT mice (Fig. 5f) paralleled by reduced levels of CXCL1 secreted from these cells after LPS (Fig. 5g). These data show that AMPK is a key protein downstream of IL-37 signalling.

IL-37 in human adipose tissue relates to insulin sensitivity. Although IL-37 is present in adipose tissue43, its role in controlling inflammation in subjects with obesity and/or insulin resistance remains unknown. Therefore, we determined IL-37 levels in subcutaneous adipose tissue samples obtained from a cohort of 80 subjects with varying levels of body mass index (BMI), insulin sensitivity and degree of adipose tissue inflammation. We compared log-normalized levels of IL-37 gene expression values in human adipose tissue with adipose tissue leptin levels, the homeostatic model for insulin resistance (HOMA-IR) and markers of adipose tissue inflammation. IL-37 gene expression levels in adipose tissue were significantly higher in subjects with lower leptin protein levels (Fig. 6a). BMI was not associated with IL-37 mRNA levels in adipose tissue (Fig. 6b). We investigated whether the inflammatory status of the adipose tissue, as quantified by the level of macrophage infiltration, was associated with IL-37 expression. Indeed, the number of CD68-positive cells in adipose tissue was inversely associated with IL-37 mRNA expression levels (Fig. 6c). IL-37 expression was associated with improved insulin sensitivity, as determined by the HOMA-IR, such that individuals with a low HOMA-IR exhibited...
higher IL-37 mRNA levels in adipose tissue compared with persons with a higher HOMA-IR (Fig. 6d). Lastly, and in line with these findings, higher insulin levels were associated with lower IL-37 mRNA levels, whereas plasma glucose levels were not related to IL-37 adipose tissue expression levels (Supplementary Fig. S11a,b).

Discussion
Adipose tissue inflammation is a key process in the development of obesity-induced insulin resistance. We demonstrate here that IL-1 family member IL-37 counteracts the detrimental effects of HFD feeding on weight, adipose tissue inflammation and systemic insulin resistance in IL-37tg mice. Moreover, treatment with recIL-37 in vivo and in vitro represses adipose tissue inflammation. We also report data suggestive of a similar function in human subjects. Together, these findings identify IL-37 as a potential new target to tackle obesity-induced insulin resistance and type 2 diabetes.

First, these conclusions are based on the observations that transgenic mice expressing human IL-37 show a reduction in...
weight gain, lower adipocyte mass and size, less adipose tissue inflammation and less insulin resistance in response to HFD feeding in comparison with WT mice fed the same diet. Second, as IL-37tg mice show greater glucose tolerance after short-term feeding, the effect of IL-37 is weight-independent. Third, IL-37 preserves IRS-1 tyrosine (Tyr) 941 phosphorylation, thereby rescuing downstream insulin signalling. Fourth, IL-37 expression in human adipose tissue is inversely correlated with adipose tissue inflammation and the presence of insulin resistance. Thus, these data support a link between IL-37 biology, adipose tissue inflammation and insulin sensitivity.

As food intake was similar between IL-37tg and control animals, other mechanisms probably underlie the decreased weight gain in IL-37tg animals during HFD-induced obesity. Interestingly, the microarray data revealed that oxidative phosphorylation and respiratory activity in WAT of the IL-37tg animals were increased compared with WT animals fed the HFD. Moreover, we show that IL-37 directly activates AMPK signalling and reduces adipocyte differentiation. This is in line with earlier described findings that overexpression of IL-37 in THP-1 cells increases AMPK and decreases mammalian target of rapamycin levels21. Moreover, other anti-inflammatory agents induce AMPK activation44. The increase of AMPK was accompanied by an increased ACC activity, providing evidence that IL-37 can activate metabolic pathways in adipocytes. It suggests the involvement of AMPK activation in the protecting effects of IL-37 against adipose tissue expansion on HFD feeding. Interestingly, recent data revealed that IL-18 signalling enhances FA oxidation via activation of AMPK signalling45. As both IL-37 and IL-18 bind to the same IL-18 receptor α chain (IL-18Rα)24, our findings suggest that IL-37 can activate AMPK signalling via similar mechanisms, leading to increased FA oxidation and alleviation from development of obesity. Consistent with this observation, an enhanced activity of BAT may partly explain the protection against the development of obesity in IL-37tg animals.

Importantly, IL-37 transgenic animals displayed markedly reduced adipose tissue inflammation, illustrated by reduced pro-inflammatory immune cell infiltration into the adipose tissue, as demonstrated by FACS analysis, qPCR and immunohistochemistry. Moreover, treatment of severely obese mice with recIL-37 reduced adipose tissue cytokine secretion, independent of body weight. In macrophages, the IL-37-dependent activation of AMPK may be aimed at counterbalancing pro-inflammatory actions. It has been previously shown that activation of AMPK in macrophages by 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR), specifically inhibits pro-inflammatory cytokine production on LPS treatment40. Through its activation of
AMPK, IL-37 may also directly inhibit inflammatory actions of immune cells. An alternative mechanism for the reduced obesity-induced inflammation is provided by our microarray analyses, showing downregulation of TLR signalling in IL-37tg mice after HFD. An inhibitory effect of IL-37 on TLR signalling in the IL-37tg mice would be consistent with a reduced ability to respond to LPS’s via triggering of TLR-2 or TLR-4 (refs 35–38,46) that can lead to macrophage activation47. Previous findings have shown that IL-37 is a fundamental inhibitor of the response to LPS21. Thus, during HFD-induced inflammatory cell infiltration into the adipose tissue, a comparable mechanism may be activated in the presence of IL-37. Through its anti-inflammatory properties, IL-37 not only reduces levels of pro-inflammatory cytokines but also prevents excessive immune cell activation in adipose tissue21.

A probable molecular mechanism through which IL-37 exerts its anti-inflammatory effects is binding to the IL-18ra24,48. There are also data that demonstrate that expression of the properties of single immunoglobulin IL-1R-related protein and IL-18ra are both necessary for the protective effects of IL-37 (ref. 49). Single immunoglobulin IL-1R-related protein engagement is known to negatively regulate TLR and IL-1 signalling50, and may also explain IL-37 inflammation-dampening effects in adipose tissue. Indeed, the microarray data revealed that IL-37 acts as an inhibitor of TLR and IL-1-mediated pathways, which confirms earlier findings21. Besides extracellular binding, IL-37 has been shown to translocate to the nucleus where it may act as a transcriptional modulator28, as is the case with nuclear translocation of another member of the IL-1 family member IL-1β51,52. Altogether, these mechanisms probably account for the anti-inflammatory actions of IL-37 in the adipose tissue. The reduction of body weight and subsequent local inflammation may also account for the markedly enhanced adiponectin levels measured in the transgenic animals, as higher adiponectin levels are generally observed in lean individuals53. Conversely, more inflammation is associated with lower adiponectin levels54.

In humans, we found that IL-37 expression in adipose tissue was inversely related to HOMA-IR. In the animal model, the presence of IL-37 protected against the detrimental effects on glucose tolerance and insulin sensitivity after HFD feeding. The effects of IL-37 appear independently of body weight changes, as IL-37tg animals were also protected against glucose intolerance on short-term HFD feeding that did not affect weight in either group. Moreover, we showed that IL-37 can preserve insulin sensitivity in vitro, by preserving phosphorylation of IRS-1 and downstream Akt for insulin signalling, via inhibition of inflammatory kinases JNK, ERK and IKKα/β that cause inhibitory serine phosphorylation of the insulin receptor substrate-1 (ref. 34). In addition, similar to IL-1 and IL-18 (refs 55–57), IL-37 affects the function of the insulin-producing β-cells. It is known that obesity can lead to islet hypertrophy and increased insulin secretion58–60. We showed that the presence of IL-37 spared pancreatic islets from hypertrophy and excessive insulin production, compared with WT mice. Overall, these findings reveal a role for IL-37 in determining insulin sensitivity. Inversely, reduced production of IL-37 may contribute to the onset of insulin resistance as absence of IL-37 may promote inflammation that directly interferes with insulin signalling routes.

Currently, regulation of IL-37 expression or its mRNA stability in human adipose tissue is unknown. Interestingly, IL-37 mRNA expression is found in the adipocyte fractions of human adipose tissue, suggesting that adipocytes are sensitive for stimuli that induce IL-37 production. Repeated high levels of postprandial free FAs probably serve as triggers for IL-1 expression61 and may also regulate IL-37 expression in adipose tissue. The co-expression of IL-37 next to IL-1 is therefore probably aimed at countering inflammation during obesity. As humans reveal an inverse correlation between inflammation in adipose tissue and expression of IL-37, it is likely to be that subjects who fail to express sufficient IL-37 locally will develop higher levels of inflammation.

All in all, our findings show that IL-37 is important during the development of obesity by counteracting adipocyte differentiation, HFD-induced adipose tissue inflammation and insulin resistance. Moreover, increased IL-37 expression in human adipose tissue is associated with enhanced insulin sensitivity and a reduction in adipose tissue inflammation. IL-37 may therefore be a target to mitigate the detrimental effects of obesity, including type 2 diabetes mellitus.

**Methods**

**Human subjects.** Subcutaneous and visceral adipose tissues were obtained from healthy donors. Characteristics of donors are listed in Table 1. For associations of

---

**Table 1** | Subject characteristics of human adipose tissue biopsies (values are mean ± s.d.).

<table>
<thead>
<tr>
<th></th>
<th>Paired VAT and SAT samples (n = 17)</th>
<th>AT biopsies (n = 80)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>52 ± 10</td>
<td>54 ± 8</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>84 ± 12</td>
<td>82 ± 15</td>
</tr>
<tr>
<td>BMI (kg m⁻²)</td>
<td>27 ± 3</td>
<td>28 ± 5</td>
</tr>
<tr>
<td>Adipose tissue depot</td>
<td>VAT and SAT</td>
<td>SAT</td>
</tr>
<tr>
<td>Fasting glucose (mmol l⁻¹)</td>
<td>6.3 ± 2.0</td>
<td>5.1 ± 0.6</td>
</tr>
<tr>
<td>Sex: M (% of total)</td>
<td>11 (65%)</td>
<td>38 (48%)</td>
</tr>
</tbody>
</table>

BMI, body mass index; M, male; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; AT, adipose tissue.

**Table 2** | Primers used for quantitative real-time PCR analysis.

<table>
<thead>
<tr>
<th>Primer name</th>
<th>Species</th>
<th>Sequence forward (5’ &gt; 3’)</th>
<th>Sequence reverse (5’ &gt; 3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>36B4</td>
<td>Mouse</td>
<td>AGGCCGTCCGGAAGTCTGTTGAG</td>
<td>GGGCAGACGTGGTGCCAGCA</td>
</tr>
<tr>
<td>MCP-1</td>
<td>Mouse</td>
<td>CCCAAAGTAGCTGCGGAGA</td>
<td>TCTGGACCTCCCTTCCTTGTG</td>
</tr>
<tr>
<td>F4/80</td>
<td>Mouse</td>
<td>CTTTGGCTATGGGTCCCCAGTC</td>
<td>GCAAGGAGGAGAGTTATCTGTG</td>
</tr>
<tr>
<td>CD11c</td>
<td>Mouse</td>
<td>CTGGATAGTCCCTCTCTCTCTCTG</td>
<td>GCACACTGTGCTGGCAACTCA</td>
</tr>
<tr>
<td>TLR-1</td>
<td>Mouse</td>
<td>TCCAGCTCTCTCTCTCTCTCTCTCT</td>
<td>TTGTAACCTGGACACAGCTCA</td>
</tr>
<tr>
<td>TLR-2</td>
<td>Mouse</td>
<td>AAAACCTCTGACAAAGGCTTCAAATC</td>
<td>ACCAGAAGTCCAGAAGGCAAAA</td>
</tr>
<tr>
<td>TLR-4</td>
<td>Mouse</td>
<td>TCTCCCTCTCCCAACCAAGAAATAGT</td>
<td>GTTCTCCTTCTCCACGAGTTAGAT</td>
</tr>
<tr>
<td>IL-37</td>
<td>Human</td>
<td>CAGGCCTCTGGGGAAGAAGGAGAT</td>
<td>CCAATGGCGGCACTTCTCAAAC</td>
</tr>
<tr>
<td>B2M</td>
<td>Human</td>
<td>ATGAGATTCTGGCTGCGGCTG</td>
<td>CCAATGGCGGCACTTCTCAAAC</td>
</tr>
</tbody>
</table>
IL-37 expression, subjects from the same CONTROL cohort were used. The total number of individuals in the control cohort was 80. Some measurements were not carried out in all subjects. Leptin was measured by enzyme-linked immunosorbent assay (ELISA) in n = 47 subjects, CD68 + cells per 1,000 adipocytes in n = 52 subjects and HOMA-IR in n = 61 subjects. All subjects gave informed consent. The studies were approved by the ethical committee of the Radboud University Medical Centre, Nijmegen.

**Mice.** IL-37tg mice on a C57Bl/6 background have been reported. WT C57Bl/6 mice were purchased from Jackson Laboratories. All animal procedures were conducted under protocols approved by the animal experimentation committee of the Radboud University Medical Centre, Nijmegen. Body weight of the animals was recorded weekly. Twenty male mice per genotype (10 weeks of age at the start of the dietary intervention) were used in the 16-week diet-intervention experiment. After a 2-week run-in period on LFD, mice were given LFD or HFD diet for 16 weeks, containing 10 or 45% kcal derived from fat, respectively (D12450B or 12451, Research Diets, New Brunswick, NJ, USA). To investigate whether IL-37 has a body weight modifying effect, we performed a 1-week short-term high-fat study using a diet containing 60% kcal derived from fat (D12492, Research Diets). For this, ten male mice per genotype were used (12 weeks of age at the start of the intervention).

**Studies on glucose homeostasis.** At the end of diet-intervention study, oGTT and ITT tests were performed. Before the oGTT test, all 40 male animals were fasted overnight and 2 g kg⁻¹ body weight of 10% glucose (Gibco, Invitrogen on HBSS containing 2% FA-free BSA) for 1 h. Cells were filtered and stained with 100-μM Hoechst 33342 (Molecular Probes, Eugene, OR, USA) and 1 μg ml⁻¹ calcein AM (Molecular Probes). A total of 40,000 events were acquired with an FC 500 Coulter Beckman. Gating strategy is shown in Supplementary Fig. 6.

**Cytokine measurements.** Plasma concentrations of insulin (Crystal Chem Inc., IL, USA), adiponectin, leptin (both R&D Systems, Minneapolis, MN, USA) were measured by ELISA. Leptin levels in human adipose tissue were measured with Milliplex (Millipore, Billerica, MA, USA). IL-37 protein levels were measured to determine levels in adipose tissue (R&D Systems).

**Histology/immunohistochemistry.** Morphometry of individual fat cells was assessed using digital image analysis. Microscopic images were digitized in 24-bit RGB (specimen level pixel size 1.28 × 1.28 μm²). Recognition of fat cells was initially performed by applying a region-growing algorithm on manually indicated seed points, and a minimum Feret diameter was calculated. For detection of macrophages/monocytes, an F4/80 antibody (Serotec, Puchheim, Germany) was used. Visualization of the complex was done using 3,3'-diaminobenzidine for 5 min. Negative controls were used by omitting the primary antibody. Haematoxylin and eosin staining of sections was done using standard protocols. Crown-like structures were counted with a microscope at a magnification of ×20, at least four images per sample. Human macrophages were visualized using CD68.

The paraffin-embedded pancreas sections (5 μm) were deparaffinized/rehydrated in Clearane (Surghulp, IL, USA) followed by ethanol and PBS serial rehydration. Antigen retrieval was performed in citrate buffer, pH 6.0, for 15 min using a steamer, and sections were blocked with CAS-BLOCK solution (Invitrogen, NY, USA) for 1 h. Sections were then stained with guinea pig anti-insulin antibody (1:600, Dako Cytomation, Glostrup, Denmark) and incubated overnight at 4 °C. Cy3-conjugated donkey-anti-guinea pig IgG (1:200, Jackson Immunoresearch, West Grove, PA, USA) was used as a secondary antibody and incubated for 2 h at 25 °C. Counterstaining was performed with 5 μg ml⁻¹ 4,6-diamidino-2-phenylindole (Sigma, Rehovot, Israel). Next, slides were mounted with PermaFluor presents (Pierce). For quantification of the islet area, β-cells were visualized by an immunohistochemical approach using an antibody against insulin (sc9168, Santa Cruz Biotechnology, Heidelberg, Germany). Quantification was performed using ImageJ software (version V1.47t). A total of n = 10 animals per group per genotype were analysed.

**Lipids.** Cholesterol, triglycerides and glucose (Liquicolor, Human GmbH, Wiesbaden, Germany) and free FA (NEPA-C, WAKO Chemicals, GmbH, Neuss, Germany) were measured enzymatically following the manufacturers’ protocols.

**FACS analyses.** After washing with DMEM + 0.1% BSA and FACS buffer (PBS + 1% BSA), the stromal vascular fraction was extracted from the epididymal mouse WAT or human adipose tissue by digestion with 0.02% collagenase type 1 (Gibco, Invitrogen on HBSS containing 2% FA-free BSA) for 1 h. Cells were filtered with a 100-μM filter and centrifuged at 200g for 10 min. Floating MAs were discarded. Four days later, the medium was only enriched by 0.1% FBS. Cells were differentiated with 1,000, 1,500, 2,000, 2,500 and 3,000 ng ml⁻¹ tunicamycin for 4 h, respectively. Differentiation was initiated by incubating the cells in medium (DMEM/F12, Gibco Life Technologies, Bleiswijk, The Netherlands) without serum in the presence of 2 μmol l⁻¹ cortisol, 25 nmol l⁻¹ dexamethasone, 0.5 μmol l⁻¹ mifepristone, 0.1 μmol l⁻¹ forskolin, 0.01 mg ml⁻¹ transferrin, 0.2 nmol l⁻¹ triiodothyronine (all from Sigma-Aldrich, St Louis, MO) and 20 nmol l⁻¹ insulin. Following this, the medium was replaced with ice-cold PBS containing phosphatase and protease inhibitors and protein extraction buffer (M-PER) according to the manufacturer’s instructions (Pierce). Human SGBS cells were differentiated with or without reoIL-37 (10 ng ml⁻¹). Differentiation was done as previously described. In short, the differentiation was initiated by incubating the cells in medium (DMEM/F12, Gibco Life Technologies, Bleiswijk, The Netherlands) without serum in the presence of 2 μmol l⁻¹ rosiglitazone, 25 nmol l⁻¹ dexamethasone, 0.5 μmol l⁻¹ mifepristone, 0.1 μmol l⁻¹ cortisol, 0.01 mg ml⁻¹ transferrin, 0.2 nmol l⁻¹ triiodothyronine (all from Sigma-Aldrich, Zwijndrecht, The Netherlands) and 20 nmol l⁻¹ insulin. Following this, the medium was replaced with ice-cold PBS containing phosphatase and protease inhibitors, except the protease inhibitors and protein extraction buffer (M-PER) as described above. After 2 weeks, light microscopy pictures were taken at magnification of ×20 and mRNA was isolated as described.

**Microarray analysis.** DNA isolated from adipose tissue from HFD-fed animals was used for microarray analysis (n = 4 animals per group). RNA quality was determined by analysis on the Agilent 2100 Bio-analyzer (Agilent Technologies). Gene expression was then evaluated using a Mouse ExpriGeneChip (Affymetrix, Santa Clara, CA) with an GCOS 2.8 and an RNA Integrity Number (RIN) score > 8. The Affymetrix WT Expression File (life Technologies) in conjunction with the Affymetrix Geneset WT Terminal Labelling kit (Affymetrix, Santa Clara, CA) was used to prepare labelled complementary DNA from 100 ng of total RNA. Samples were hybridized on Affymetrix Mouse Genome 430 2.0 arrays. Gene 1.0 ST arrays. Differences in gene expression between WT and IL-37-tg-derived epididymal tissue were determined using gene set enrichment analysis. The Enrichment Map plug-in for Cytoscape was used for the analysis.
visualization and interpretation of the gene set enrichment analysis results. The cut-off values were P<0.01.

**Statistical analysis.** Data are shown as the mean ± s.e.m. Differences between groups were statistically analysed using Student’s t test, and differences among the four groups were analysed with analysis of variance followed by post-hoc Bonferroni tests in Graphpad Prism 5.0. When necessary, results were log-transformed to normalize the data. A P-value <0.05 was considered significant.

**References**

1. WHO. WHO Fact Files: Ten Facts on Obesity (WHO, 2010).


29. Kumar, S. et al. Interleukin-1F7B (IL-1F7/H) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. *Cytokine* 18, 61–72 (2001).


**Acknowledgements**

R.S. was supported by a Ruby Grant of the Dutch Diabetes Research Foundation. M.G.N. was supported by a Vici Grant from the Netherlands Organization for Scientific Research (NWO). P.B. was supported by Deutsche Forschungsgemeinschaft BU 1222/3-3. We thank Tim Koenen for help in collecting the human adipose samples.

**Author contributions**

D.B., J.A.D. and R.S. performed experiments and analyses, and wrote the manuscript. H.J.J. collected the human adipose tissue samples. A.H., G.G., F.L., S.L., H.E., E.C.L. and S.H.K. performed and contributed to experiments. P.B. helped in animal study and checked manuscript. A.R.M. and H.T. performed and analysed the *in vitro* part of the manuscript, and checked the manuscript. M.V.B and M.M. helped in microarray study. S.K. helped in the microarray study and checked the manuscript. L.A.J., M.G.N., C.J.T., C.A.D. and R.S. supervised the entire study.

**Additional information**

Accession codes: Microarray data have been deposited in GEO repository under accession code GSE58952.

**Supplementary Information** accompanies this paper at http://www.nature.com/naturecommunications

**Competing financial interests:** The authors declare no competing financial interests.

**Reprints and permission** information is available online at http://npg.nature.com/reprintsandpermissions/

**How to cite this article:** Ballak, D. B. *et al.* IL-37 protects against obesity-induced inflammation and insulin resistance. *Nat. Commun.* 5:4711 doi: 10.1038/ncomms5711 (2014).
Corrigendum: IL-37 protects against obesity-induced inflammation and insulin resistance


Nature Communications 5:4711 doi: 10.1038/ncomms5711 (2014); Published 3 Sep 2014; Updated 12 Jan 2015

The financial support for this Article was not fully acknowledged. The Acknowledgements should have read:

R.S. was supported by a Ruby Grant of the Dutch Diabetes Research Foundation. C.A.D. was supported by the National Institutes of Health (grant number AI15614). M.G.N. was supported by a Vici Grant from the Netherlands Organization for Scientific Research (NWO). P.B. was supported by Deutsche Forschungsgemeinschaft BU 1222/3-3. We thank Tim Koenen for help in collecting the human adipose samples.